Sign In
Buy MESO
$14.17
-0.380 (-2.61%)
At Close: Jul 31, 2026
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
08:57pm, Wednesday, 29'th Jul 2026
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
01:01pm, Friday, 17'th Jul 2026
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
08:35pm, Monday, 13'th Jul 2026
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
07:59am, Saturday, 11'th Jul 2026
Mesoblast transitions to a commercial-stage company, anchored by FDA-approved Ryoncil and robust early revenue growth. Ryoncil's regulatory, reimbursement, and manufacturing precedents de-risk MESO's
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
08:30pm, Thursday, 09'th Jul 2026
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a B
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
08:59pm, Wednesday, 24'th Jun 2026
Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
08:55pm, Wednesday, 29'th Apr 2026
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
08:55pm, Wednesday, 29'th Apr 2026
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
08:53pm, Tuesday, 28'th Apr 2026
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
08:10pm, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an
First Look: JPM beats, RVMD surges, NXST-TGNA paused
07:37am, Tuesday, 14'th Apr 2026
Stock News JPMorgan tops Q1 estimates: JPMorgan Chase (JPM) posted Q1 EPS of $5.94 on revenue of $50.54B, beating estimates on stronger fixed income trading and
Gregory George Acquires 1,981,890 Shares of Mesoblast (NASDAQ:MESO) Stock
04:19am, Sunday, 12'th Apr 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George bought 1,981,890 shares of Mesoblast stock in a transaction that occurred on Thursday, April 9th. The stock was purchased at
Gregory George Purchases 4,000,000 Shares of Mesoblast (NASDAQ:MESO) Stock
04:19am, Sunday, 12'th Apr 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 4,000,000 shares of the business's stock in a transaction on Saturday, April 4th. The stock was acquired at an avera
Gregory George Buys 2,324,072 Shares of Mesoblast (NASDAQ:MESO) Stock
04:19am, Sunday, 12'th Apr 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 2,324,072 shares of the stock in a transaction dated Friday, April 10th. The shares were purchased at an average pri
